HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.

AuthorsWarren Fiskus, Taghi Manshouri, Christine Birdwell, Christopher P Mill, Lucia Masarova, Prithviraj Bose, Tapan M Kadia, Naval Daver, Courtney D DiNardo, Gautam Borthakur, Joseph D Khoury, Srdan Verstovsek, Kapil N Bhalla
JournalBlood cancer journal (Blood Cancer J) Vol. 12 Issue 1 Pg. 23 (01 31 2022) ISSN: 2044-5385 [Electronic] United States
PMID35102145 (Publication Type: Letter)
Chemical References
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • CDK9 protein, human
  • Cyclin-Dependent Kinase 9
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Cyclin-Dependent Kinase 9 (antagonists & inhibitors)
  • Humans
  • Leukemia, Myeloid, Acute (drug therapy)
  • Mice
  • Myeloproliferative Disorders (drug therapy)
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: